Tumor prevention by a xanthate compound in experimental mouse-skin tumorigenesis.
The antiviral and antitumoral compound tricyclodecan-9-yl-xanthogenate (D609), which is an inhibitor of protein kinase C activation, has been used for tumor prevention in vivo. When applied chronically together with 12-O-tetradecanoylphorbol-13-acetate (TPA) in the classic initiation-promotion mouse-skin model, D609 prevented tumor induction in a dose-dependent manner. At the concentration that inhibited tumor formation by 97%, no toxic effects were detected and the TPA-induced hyperplasia remained unaffected. As D609 failed to prevent the activity of a chronically applied carcinogen, it is concluded that the observed tumor prevention achieved with D609 is tumor-promotion-specific and is not due to killing of tumor cells.
Fürstenberger
G
G
Institute for Biochemistry, German Cancer Research Center, Heidelberg, FRG.
Amtmann
E
E
Marks
F
F
Sauer
G
G
D015127:9,10-Dimethyl-1,2-benzanthracene; D000279:Administration, Cutaneous; D000818:Animals; D000970:Antineoplastic Agents; D000998:Antiviral Agents / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D002277:Carcinoma / Q000139:chemically induced / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D009636:Norbornanes; D010212:Papilloma / Q000139:chemically induced / Q000517:prevention & control; D012878:Skin Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D013755:Tetradecanoylphorbol Acetate; D013859:Thiocarbamates; D013871:Thiones / Q000494:pharmacology*
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001952:Bridged-Ring Compounds; D009636:Norbornanes; D013859:Thiocarbamates; D013871:Thiones; D015127:9,10-Dimethyl-1,2-benzanthracene; C046498:tricyclodecane-9-yl-xanthogenate; C058794:propylxanthogenate; D013755:Tetradecanoylphorbol Acetate